Atlanta Capital Management Co. L L C Has $299.22 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Atlanta Capital Management Co. L L C increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,055,075 shares of the medical research company’s stock after purchasing an additional 67,099 shares during the period. Thermo Fisher Scientific accounts for 1.6% of Atlanta Capital Management Co. L L C’s portfolio, making the stock its 10th largest holding. Atlanta Capital Management Co. L L C owned about 0.27% of Thermo Fisher Scientific worth $299,219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of TMO. Laurel Wealth Advisors LLC raised its position in shares of Thermo Fisher Scientific by 104.3% during the 1st quarter. Laurel Wealth Advisors LLC now owns 94 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 48 shares during the last quarter. Stonebridge Financial Planning Group LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $32,000. Ballast Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $35,000. Lloyd Advisory Services LLC. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $44,000. Finally, Virtus ETF Advisers LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $44,000. Hedge funds and other institutional investors own 87.65% of the company’s stock.

Shares of Thermo Fisher Scientific stock traded up $0.54 during trading hours on Monday, reaching $349.73. 28,999 shares of the company’s stock were exchanged, compared to its average volume of 1,339,427. The company has a 50 day moving average of $332.02 and a two-hundred day moving average of $318.84. Thermo Fisher Scientific Inc. has a fifty-two week low of $250.21 and a fifty-two week high of $351.86. The company has a current ratio of 2.32, a quick ratio of 1.69 and a debt-to-equity ratio of 0.67. The stock has a market cap of $138.00 billion, a P/E ratio of 38.31, a P/E/G ratio of 2.34 and a beta of 1.04.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 22nd. The medical research company reported $2.94 EPS for the quarter, topping the Zacks’ consensus estimate of $2.79 by $0.15. Thermo Fisher Scientific had a net margin of 14.31% and a return on equity of 17.25%. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6.18 billion. During the same period in the prior year, the business posted $2.81 EPS. The company’s quarterly revenue was up 1.7% on a year-over-year basis. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 11.92 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.22 per share. The ex-dividend date is Friday, June 12th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio is 7.13%.

Several equities analysts have recently issued reports on TMO shares. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $340.00 to $341.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. SVB Leerink boosted their price target on shares of Thermo Fisher Scientific from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, April 23rd. Citigroup boosted their price target on shares of Thermo Fisher Scientific from $365.00 to $390.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Finally, Wells Fargo & Co boosted their price target on shares of Thermo Fisher Scientific from $300.00 to $340.00 and gave the company an “equal weight” rating in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $349.31.

In other news, COO Mark Stevenson sold 25,000 shares of the stock in a transaction dated Friday, April 24th. The shares were sold at an average price of $328.03, for a total transaction of $8,200,750.00. Following the completion of the transaction, the chief operating officer now directly owns 73,538 shares in the company, valued at approximately $24,122,670.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 30,000 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $333.02, for a total transaction of $9,990,600.00. Following the completion of the sale, the chief executive officer now directly owns 304,946 shares in the company, valued at $101,553,116.92. The disclosure for this sale can be found here. Corporate insiders own 0.44% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: How to track put option volume

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.